文献速递心律失常

脉冲场消融与常规热消融治疗阵发性房颤:复发性房性心律失常负荷对比

Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden.
PubMed 文献 · J Am Coll Cardiol · 2024-05-18

ADVENT随机试验亚组分析纳入593例症状性药物难治性阵发性房颤患者,比较脉冲场消融(PFA)与热消融(射频/冷冻球囊)术后房性心律失常(AA)负荷。结果显示AA负荷超过0.1%与生活质量下降和临床干预增加相关,PFA组残余AA负荷<0.1%的患者比例更高(OR 1.5,95%CI 1.0-2.3,P=0.04),尤其在既往I/III类抗心律失常药物失败者中更明显(OR 2.5,95%CI 1.4-4.3,P=0.002)。

要点

  • 术后AA负荷>0.1%与生活质量下降及再消融、电复律、住院增加相关。
  • PFA组残余AA负荷<0.1%的比例高于热消融组(OR 1.5,P=0.04)。
  • 既往I/III类抗心律失常药物失败者从PFA中获益更明显(OR 2.5,P=0.002)。

核心结论

  • 与热消融相比,PFA更常使AA负荷低于临床显著阈值0.1%。
  • AA负荷超过0.1%与生活质量降低和临床干预增加相关。

研究设计与样本

  • ADVENT随机试验的事后分析,纳入593例症状性药物难治性阵发性房颤患者(PFA组299例,热消融组294例)。
  • 术后通过每周或症状触发的经电话心电图监测及6、12个月72小时动态心电图计算AA负荷。

主要发现

  • AA负荷超过0.1%与生活质量显著降低及再消融、电复律、住院增加相关。
  • PFA组残余AA负荷<0.1%的患者比例高于热消融组(OR 1.5,95%CI 1.0-2.3,P=0.04)。
  • 既往I/III类抗心律失常药物失败者中,PFA组残余AA负荷低于热消融组(OR 2.5,95%CI 1.4-4.3,P=0.002)。
  • 术前仅使用II/IV类抗心律失常药物者,两种消融方式AA负荷无差异。

关键数值与推荐

  • AA负荷临床显著阈值为0.1%。
  • PFA组残余AA负荷<0.1%的OR为1.5(95%CI 1.0-2.3,P=0.04)。
  • 既往I/III类抗心律失常药物失败者中PFA组OR为2.5(95%CI 1.4-4.3,P=0.002)。

临床怎么用

  • 对症状性药物难治性阵发性房颤,PFA可能更有利于实现低AA负荷。
  • 既往I/III类抗心律失常药物失败者优先考虑PFA可能获益更多。
  • 术后应关注AA负荷而非仅30秒复发,负荷>0.1%提示需加强干预。

局限性

  • 为ADVENT试验的事后分析,结果需前瞻性验证。
  • AA负荷基于间歇性监测(每周经电话心电图及6、12个月动态心电图),可能低估无症状发作。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ADVENT randomized trial revealed no significant difference in 1-year freedom from atrial arrhythmias (AA) between thermal (radiofrequency/cryoballoon) and pulsed field ablation (PFA). However, recent studies indicate that the postablation AA burden is a better predictor of clinical outcomes than the dichotomous endpoint of 30-second AA recurrence. OBJECTIVES: The goal of this study was to determine: 1) the impact of postablation AA burden on outcomes; and 2) the effect of ablation modality on AA burden. METHODS: In ADVENT, symptomatic drug-refractory patients with paroxysmal atrial fibrillation underwent PFA or thermal ablation. Postablation transtelephonic electrocardiogram monitor recordings were collected weekly or for symptoms, and 72-hour Holters were at 6 and 12 months. AA burden was calculated from percentage AA on Holters and transtelephonic electrocardiogram monitors. Quality-of-life assessments were at baseline and 12 months. RESULTS: From 593 randomized patients (299 PFA, 294 thermal), using aggregate PFA/thermal data, an AA burden exceeding 0.1% was associated with a significantly reduced quality of life and an increase in clinical interventions: redo ablation, cardioversion, and hospitalization. There were more patients with residual AA burden <0.1% with PFA than thermal ablation (OR: 1.5; 95% CI: 1.0-2.3; P = 0.04). Evaluation of outcomes by baseline demographics revealed that patients with prior failed class I/III antiarrhythmic drugs had less residual AA burden after PFA compared to thermal ablation (OR: 2.5; 95% CI: 1.4-4.3; P = 0.002); patients receiving only class II/IV antiarrhythmic drugs pre-ablation had no difference in AA burden between ablation groups. CONCLUSIONS: Compared with thermal ablation, PFA more often resulted in an AA burden less than the clinically significant threshold of 0.1% burden. (The FARAPULSE ADVENT PIVOTAL Trial PFA System vs SOC Ablation for Paroxysmal Atrial Fibrillation [ADVENT]; NCT04612244).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Reddy VY, Mansour M, Calkins H, et al. Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden. J Am Coll Cardiol. 2024. PMID: 38864538. doi:10.1016/j.jacc.2024.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。